Shanghai Ambiopharm, Inc: FDA NDC listings

Does Shanghai Ambiopharm, Inc list GLP-1 drug products with FDA?

Yes. FDA’s NDC Directory files, read Nov 15, 2026, list 2 products naming liraglutide and semaglutide under the labeler name “Shanghai Ambiopharm, Inc”, in these marketing categories: BULK INGREDIENT (2). A listing is the labeler’s own submission; FDA says it does not indicate that FDA has verified the information or that the product is FDA-approved.

GLP-1 listings
2
Marketing categories
BULK INGREDIENT (2)
Drugs named
Liraglutide, Semaglutide
Marketing start dates
Dec 12, 2017 to Dec 11, 2021

This page exists because the labeler has 2 or more compounded or bulk ingredient GLP-1 listings in FDA’s NDC files and no other page here under the same name. FDA’s NDC files give a labeler name, not an address or FEI number, so this index has not tied this labeler to any FDA inspection, letter or import record.

Listings

41524-0011Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTDec 12, 2017None givenDec 31, 2027Unfinished drugs
41524-0012Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTDec 11, 2021None givenDec 31, 2027Unfinished drugs

FDA’s own words on the NDC Directory page (content current as of Mar 4, 2026):

Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved. The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file. Assignment of an NDC number does not in any way denote FDA approval of the product. Any representation that creates an impression of FDA approval because a product has an NDC number is misleading and violates federal law. Inclusion in the NDC Directory or assignment of an NDC number does not mean a product is a drug as defined by federal law.

All GLP-1 NDC listings.

This page restates listings from FDA’s NDC Directory files as FDA publishes them. A listing is the labeler’s own submission to FDA, not an FDA approval and not a finding by this site, and it says nothing about inspections or enforcement. Follow the source link for FDA’s files. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.